Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in Enterobacterales

被引：8
|
作者：
Sadek, Mustafa [1 ,2 ]
Duran, Juan Bosch [1 ]
Poirel, Laurent [1 ,3 ]
Nordmann, Patrice [1 ,3 ,4 ]
机构：
[1] Univ Fribourg, Fac Sci & Med, Med & Mol Microbiol, Fribourg, Switzerland
[2] South Valley Univ, Fac Vet Med, Dept Food Hyg & Control, Qena, Egypt
[3] Univ Fribourg, Swiss Natl Reference Ctr Emerging Antibiot Resista, Fribourg, Switzerland
[4] Univ Lausanne, Univ Hosp Ctr, Inst Microbiol, Lausanne, Switzerland
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年 / 67卷 / 05期
基金：
瑞士国家科学基金会;
关键词：
minor carbapenemases; SME; Enterobacterales; imipenem-relebactam; FRI; NMC-A; carbapenemase;
D O I：
10.1128/aac.00078-23
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The in vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, and cefiderocol was evaluated against both clinical and isogenic enterobacterial isolates producing carbapenemases of the SME, NmcA, FRI, and IMI types. Ceftazidime-avibactam and meropenem-vaborbactam showed the highest activity against all tested isolates; imipenem-relebactam showed only moderate activity. All isolates remained susceptible to cefiderocol. Furthermore, avibactam and vaborbactam have greater inhibitory activity than relebactam against the tested carbapenemases. Overall, ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol were the most effective therapeutic options for treating infections caused by the tested minor carbapenemase producers.
引用
收藏
页数：5
相关论文
共 50 条
  • [1] In vitro antimicrobial activity of six novel β-lactam and β-lactamase inhibitor combinations and cefiderocol against NDM-producing Enterobacterales in China
    Liu, Xinmeng
    Li, Ziyao
    Zhang, Feilong
    Yang, Xinrui
    Lei, Zichen
    Li, Chen
    Wu, Yongli
    Zhao, Jiankang
    Zhang, Yulin
    Hu, Yanning
    Shen, Fangfang
    Wang, Pingbang
    Yang, Junwen
    Liu, Yulei
    Shi, Huihui
    Lu, Binghuai
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2025, 65 (02)
  • [2] In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
    Santerre Henriksen, Anne
    Arena, Fabio
    Attwood, Marie
    Canton, Rafael
    Gatermann, Soren
    Naas, Thierry
    Morrissey, Ian
    Longshaw, Christopher
    MICROBIOLOGY SPECTRUM, 2024, 12 (08):
  • [3] Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa
    Poirel, Laurent
    de la Rosa, Jose-Manuel Ortiz
    Sadek, Mustafa
    Nordmann, Patrice
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (04)
  • [4] β-lactam antibiotic and β-lactamase inhibitor combinations
    Lee, NLS
    Yuen, KY
    Kumana, CR
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (04): : 386 - 388
  • [5] β-lactam/β-lactamase inhibitor combinations: an update
    Tehrani, Kamaleddin H. M. E.
    Martin, Nathaniel I.
    MEDCHEMCOMM, 2018, 9 (09) : 1439 - 1456
  • [6] Citrobacter freundii resistant to novel β-lactamase inhibitor combinations and cefiderocol, co-producing class A, B and D carbapenemases encoded by transferable plasmids
    Riccobono, Eleonora
    Salvetti, Sara
    Coppi, Marco
    Montenora, Iolanda
    Di Pilato, Vincenzo
    Rossolini, Gian Maria
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (07) : 1677 - 1682
  • [7] Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations The "Price of Progress"
    Papp-Wallace, Krisztina M.
    Mack, Andrew R.
    Taracila, Magdalena A.
    Bonomo, Robert A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2020, 34 (04) : 773 - +
  • [8] Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa
    Gonzalez-Pinto, Lucia
    Alonso-Garcia, Isaac
    Blanco-Martin, Tania
    Camacho-Zamora, Pablo
    Fraile-Ribot, Pablo Arturo
    Outeda-Garcia, Michelle
    Lasarte-Monterrubio, Cristina
    Guijarro-Sanchez, Paula
    Maceiras, Romina
    Moya, Bartolome
    Juan, Carlos
    Vazquez-Ucha, Juan Carlos
    Beceiro, Alejandro
    Oliver, Antonio
    Bou, German
    Arca-Suarez, Jorge
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (10) : 2591 - 2597
  • [9] β-Lactam/β-Lactamase Inhibitor Combinations: From Then to Now
    Toussaint, Kimberly A.
    Gallagher, Jason C.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (01) : 86 - 98
  • [10] Clinical Role of β-Lactam/β-Lactamase Inhibitor Combinations
    Nelson Lee
    Kwok-Yung Yuen
    Cyrus R. Kumana
    Drugs, 2003, 63 : 1511 - 1524
12345